GastrOesophageal Tumor, Immune Microenvionnment (GOTIM)
ConditionGastroEsophageal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Leon Berard
About this trial
This trial is a prospective, monocentric, non-therapeutic, interventional cohort study aiming to decipher the immune TME through standard neoadjuvant CT in resectable G/GEJ adenocarcinomas. This study will also longitudinally monitor MRD during neoadjuvant and adjuvant therapy.
Eligibility criteria
Qualifiers
Male or female patient > 18 years of age on day of signing informed consent.
Histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III to be treated with standard neoadjuvant treatment.
Surgery of primary tumor to be done at Centre Léon Bérard.
Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells.
Disqualifiers
Any condition contraindicated with blood sampling procedures required by the protocol.
Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer
Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
Pregnant or breast-feeding woman.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov